Real world data is becoming increasingly important in the post-marketing stages of drug development. Additionally, complex and distributed trial designs often require tools to monitor study outcomes objectively and remotely.

The Byteflies platform, which is the engine behind our Care@Home applications, is a certified, audited, and validated system for collecting wearable-based endpoints in your clinical trial or as part of an real world data study.

Accelerate clinical trials in Pharma. Bringing a new drug to market costs $1B-10B and takes 10-15 years so all innovations that attempt to improve the drug development process are important. Distributed clinical trials are one such innovation. They increase the number of subjects that can be enrolled at once, and the quality and quantity of real-world evidence that is generated. Wearable health devices are the crux of distributed trials as they enable 24/7 vital sign collection, escape the physical barriers of trial site, and provide a direct line of communication with the subject, no matter where they are. By being monitored from the comfort of their own homes, patient recruitment goes much more quickly, which also can help shorten the duration of clinical trials. All of this could speed up drug trials by up to one or two years.

A tool for value-based healthcare. Proving the efficacy of a drug, both in the short and long-term is becoming increasingly important for providers. A wearable health device can extend a care strategy into the home environment, provide the means for medical professionals to react more promptly to relapses, generate continuous and objective cohort data, and monitor treatment adherence.

Validate your new technology. New biosensors or signal processing algorithms should be benchmarked out of the lab to verify their performance. We can provide you with the tools to implement your new technology into a wearable device, and test it under real-world circumstances.

Digital biomarkers. The age of powerful and accessible traditional biomarkers has only just began, but the advent of a new category of digital biomarkers is already upon us. While the latter are usually less specific, they more than make up for this by their always-on nature. Our platform can generate the rich datasets needed to develop algorithms for advanced multimodal vital sign monitoring.